Facinicline

DB05586InvestigationalSmall molecule

Investigated for use/treatment in alzheimer's disease, neurologic disorders, and schizophrenia and schizoaffective disorders.

Mechanism: Pharmacologically active on Neuronal acetylcholine receptor subunit alpha-7
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease, neurologic disorders, and schizophrenia and schizoaffective disorders.Curator reviewed
Formula / weight: C₁₅H₁₈N₄O · 270.336 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyTXCYUSKWBHUVEP-CYBMUJFWSA-NSMILES[H]N([C@@H]1CN2CCC1CC2)C(=O)C1=NN([H])C2=CC=CC=C12

Targets

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Facinicline, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.